[Presentation of a randomized multicenter study protocol. "Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse"].
D000230:Adenocarcinoma / Q000517:prevention & control* / Q000601:surgery; D000368:Aged; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000517:prevention & control* / Q000601:surgery; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009392:Nephrectomy; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012307:Risk Factors
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Presentazione di protocollo di studio multicentrico randomizzato. "Valutazione dell'efficacia dell'interferone adiuvante dopo nefrectomia radicale nel carcinoma renale ad alto rischio di ricaduta".